- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07227012
Een onderzoek om te leren over de studiemedicatie PF-08634404 als enkele behandeling en combinatiebehandeling bij volwassen deelnemers met een leverkanker genaamd hepatocellulair carcinoom, die te vergevorderd is om chirurgisch te worden verwijderd en mogelijk is uitgezaaid naar andere delen van het lichaam.
EEN INTERVENTIONELE OPEN-LABEL FASE 1B/2-STUDIE OM DE VEILIGHEID, FARMACOKINETIEK EN VOORLOPIGE EFFECTIVITEIT VAN PF-08634404 ALS MONOTHERAPIE EN COMBINATIETHERAPIE TE EVALUEREN BIJ VOLWASSEN DEELNEMERS MET NIET-RESECEERBARE LOKAAL GEVORDERDE OF METASTATISCHE HEPATOCELLULAIRE CARCINOOM
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
- Be 18 years or older.
- Have locally advanced or metastatic HCC.
- Is not a candidate for complete surgical or loco-regional therapies.
- Have not received any whole-body treatment for HCC.
Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Pfizer CT.gov Call Center
- Telefoonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studie Locaties
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Werving
- Zhongshan Hospital,Fudan University
-
-
-
-
-
Fukuoka, Japan, 811-1395
- Werving
- National Hospital Organization Kyushu Cancer Center
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Werving
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Werving
- National Cancer Center Hospital East
-
-
Osaka
-
Sakai, Osaka, Japan, 590-0197
- Werving
- Kindai University Hospital- Osaka Medical Campus
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0045
- Werving
- National Cancer Center Hospital
-
-
-
-
-
San Juan, Puerto Rico, 00909
- Werving
- Pan American Center for Oncology Trials, LLC
-
-
United States of America
-
Dorado, United States of America, Puerto Rico, 00646
- Werving
- Pan American Center for Oncology Trials, LLC - Dorado Office
-
Mayagüez, United States of America, Puerto Rico, 00680
- Werving
- Pan American Center for Oncology Trials, LLC - Mayaguez Office
-
Ponce, United States of America, Puerto Rico, 00730
- Werving
- Pan American Center for Oncology Trials, LLC - Ponce Office
-
-
-
-
-
Taichung, Taiwan, 407
- Werving
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 704
- Werving
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10002
- Werving
- National Taiwan University Hospital
-
Taipei, Taiwan, 112
- Werving
- Taipei Veterans General Hospital
-
-
-
-
California
-
Irvine, California, Verenigde Staten, 92612
- Werving
- Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Irvine, California, Verenigde Staten, 92612
- Werving
- UCI Health - Irvine Infusion Pharmacy ACC
-
Irvine, California, Verenigde Staten, 92612
- Werving
- UCI Health - Irvine
-
Los Angeles, California, Verenigde Staten, 90033
- Werving
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, Verenigde Staten, 90033
- Werving
- Keck Hospital of USC
-
Los Angeles, California, Verenigde Staten, 90033
- Werving
- USC/Norris Comprehensive Cancer Center / Investigational Drug Services
-
Los Angeles, California, Verenigde Staten, 90033
- Werving
- Los Angeles General Medical Center
-
Los Angeles, California, Verenigde Staten, 90025
- Werving
- START Los Angeles, LLC
-
Los Angeles, California, Verenigde Staten, 90067
- Werving
- LACN Century City
-
Orange, California, Verenigde Staten, 92868
- Werving
- UC Irvine Health - Chao Family Comprehensive Cancer Center
-
Pasadena, California, Verenigde Staten, 91105
- Werving
- Keck Medical Center of USC Pasadena
-
-
Florida
-
Land O' Lakes, Florida, Verenigde Staten, 34638
- Werving
- Moffitt Cancer Center at Speros
-
Ruskin, Florida, Verenigde Staten, 33570
- Werving
- Moffitt Cancer Center at SouthShore
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Moffitt Cancer Center - McKinley Campus
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Moffitt Cancer Center
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Moffitt McKinley Hospital
-
Tampa, Florida, Verenigde Staten, 33607
- Werving
- Moffitt Cancer Center - International Plaza
-
Wesley Chapel, Florida, Verenigde Staten, 33544
- Werving
- Moffitt Cancer Center at Wesley Chapel
-
-
Illinois
-
Shiloh, Illinois, Verenigde Staten, 62269
- Werving
- Siteman Cancer Center - Shiloh
-
Shiloh, Illinois, Verenigde Staten, 62269
- Werving
- Memorial Hospital
-
-
Minnesota
-
Coon Rapids, Minnesota, Verenigde Staten, 55433
- Werving
- Allina Health Cancer Institute - Mercy Hospital
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Werving
- Allina Health Cancer Institute - Abbott Northwestern Hospital
-
Saint Paul, Minnesota, Verenigde Staten, 55102
- Werving
- Allina Health Cancer Institute - United Hospital
-
-
Missouri
-
City of Saint Peters, Missouri, Verenigde Staten, 63376
- Werving
- Siteman Cancer Center - St. Peters
-
Creve Coeur, Missouri, Verenigde Staten, 63141
- Werving
- Siteman Cancer Center - West County
-
Florissant, Missouri, Verenigde Staten, 63031
- Werving
- Siteman Cancer Center - North County
-
Kansas City, Missouri, Verenigde Staten, 64111
- Werving
- Saint Luke's Hospital of Kansas City
-
Kansas City, Missouri, Verenigde Staten, 64111
- Werving
- Saint Luke's Cancer Institute
-
St Louis, Missouri, Verenigde Staten, 63108
- Werving
- Siteman Cancer Center
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- Washington University School of Medicine - Siteman Cancer Center
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- Barnes-Jewish Hospital
-
St Louis, Missouri, Verenigde Staten, 63129
- Werving
- Siteman Cancer Center - South County
-
-
Nevada
-
Reno, Nevada, Verenigde Staten, 89502
- Werving
- Renown Regional Medical Center
-
Reno, Nevada, Verenigde Staten, 89502
- Werving
- Renown Health Medical Oncology
-
Reno, Nevada, Verenigde Staten, 89502
- Werving
- Renown Office of Clinical Research
-
-
North Carolina
-
Cary, North Carolina, Verenigde Staten, 27518
- Werving
- Duke Cancer Center Cary
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke Cancer Center
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke University - Main Hospital and Clinics
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke Cancer Center - Investigational Chemotherapy Service
-
Raleigh, North Carolina, Verenigde Staten, 27609
- Werving
- Duke Cancer Center Raleigh
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- Werving
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Werving
- AHN Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15212
- Werving
- AHN Cancer Institute at Allegheny General Hospital
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98101
- Werving
- Virginia Mason Medical Center
-
Seattle, Washington, Verenigde Staten, 98109
- Werving
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Verenigde Staten, 98195
- Werving
- University of Washington Medical Center- Montlake
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- 18 years of age or older at screening.
- Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
- Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
- At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
- Adequate hepatic, liver, and renal function
- No prior systemic therapy for HCC.
- ECOG performance status 0 or 1
- Child-Pugh Class A
Key Exclusion Criteria:
- Moderate or severe ascites.
- History of hepatic encephalopathy.
- Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
- Clinically significant risk of hemorrhage or fistula.
- Participants with any history of another malignancy within 3 years.
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
- Clinically significant cardiovascular disease within 6 months prior to the first dose.
- Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
- History of severe bleeding tendency or coagulation dysfunction.
- History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
- Participants with acute, chronic or symptomatic infections.
- Participants with history of immunodeficiency.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Phase 1b
Participants will be allocated to sequential dose levels of PF-08634404 and ipilimumab. |
Solution for infusion Solution for infusion
Andere namen:
|
|
Experimenteel: Phase 2
Participants will be randomized to receive either PF-08634404 monotherapy or PF-08634404 combined with ipilimumab. |
Solution for infusion Solution for infusion
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants With Adverse Events
Tijdsspanne: Through end of study and up to approximately 24 months
|
Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through end of study and up to approximately 24 months
|
|
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
Tijdsspanne: Through 90 days after the last dose of study intervention; Approximately 24 months
|
DLTs are a predefined set of adverse events that are at least possibly related to any or all of the study interventions. The number of participants who experienced DLTs during the DLT observation period. |
Through 90 days after the last dose of study intervention; Approximately 24 months
|
|
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Tijdsspanne: Approximately 24 months
|
ORR is the proportion of participants with a best overall response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
Tijdsspanne: Approximately 24 months
|
The doses of PF-08634404 and ipilimumab selected to be used in combination based on safety, tolerability, pharmacokinetics, and initial anti-tumor efficacy from Phase 2. |
Approximately 24 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Phase 1b: Confirmed Objective Response Rate (ORR) using RECIST 1.1 as assessed by investigator
Tijdsspanne: Approximately 24 months
|
ORR is the proportion of participants with a best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Duration of Response (DOR) per RECIST 1.1 by investigator
Tijdsspanne: Approximately 24 months
|
DOR is the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Progression Free Survival (PFS) per RECIST 1.1 by investigator
Tijdsspanne: Approximately 24 months
|
PFS is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Overall Survival (OS)
Tijdsspanne: Approximately 24 months
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 24 months
|
|
Number of Participants With Clinical Laboratory Abnormalities
Tijdsspanne: Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing |
Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
|
Pharmacokinetics (PK): Serum concentrations of PF-08634404
Tijdsspanne: Up to 24 months
|
Predose and/or postdose concentrations of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
|
Incidence of antidrug antibody against PF-08634404
Tijdsspanne: Up to 24 months
|
To evaluate immunogenicity of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Pfizer CT.gov Call Center, Pfizer
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Neoplasmata per histologisch type
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Lever Ziekten
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Carcinoom
- Carcinoom, hepatocellulair
- Lever neoplasmata
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Ipilimumab
Andere studie-ID-nummers
- C6461013
- 2025-523525-17-00 (Ctis)
- Symbiotic-GI-13 (Andere identificatie: Pfizer)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .